OKYO Pharma Limited (OKYO)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
OKYO Pharma Ltd — 6-K Filing
# 📜 What This Document Is This is a **6-K filing**, which is a report foreign companies (like OKYO, based in the UK) submit to the SEC to announce major news. This specific filing is a press release sharing updates about an upcoming scientific conference. 👉 In simple terms, it's a company news an
SEC filings
All filings →Insider trades
All insider trades →OKYO Pharma Limited has no reported insider trades in the last 90 days.